There is no specific antidote for VENCLEXTA. For patients who experience overdose, closely monitor and provide appropriate supportive treatment; during ramp-up phase interrupt VENCLEXTA and monitor carefully for signs and symptoms of TLS along with other toxicities [see Recommended Dosage for Chronic Lymphocytic Leukemia, Recommended Dosage for Acute Myeloid Leukemia, Risk Assessment and Prophylaxis for Tumor Lysis Syndrome, and Dosage Modifications for Adverse Reactions under Dosage & Administration]. Based on venetoclax large volume of distribution and extensive protein binding, dialysis is unlikely to result in significant removal of venetoclax.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign Out
